Access Vascular Appoints MedTech Veteran to Head MIMIX™ Commercialization
Key leadership hire adds momentum to biomaterial catheter growth and expansion
Billerica, MA –December 1, 2023 - Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications with its advanced biomaterial platform, today announced the appointment of Dennis Byrne to the newly created role of Vice President of Sales and Marketing.
The patented MIMIX™ material used in AVI’s HydroPICC®, HydroPICC® Dual, and HydroMID® catheters has shown a six-fold decrease in complications compared with standard polyurethane catheter material.[i] MIMIX™ resulted in a four-log reduction in bacterial adhesion using an in vitro blood loop model, and reduced thrombus accumulation by 96 percent compared to a polyurethane catheter, according to a recent study.[ii]
Byrne, who will oversee AVI’s sales and marketing efforts, has more than 25 years of experience in the medical device industry. Most recently, he served as National Director of Commercial Strategy and Sales for Clot Management for Boston Scientific, following that company’s 2019 acquisition of BTG. Byrne also held a variety of commercial and sales positions at leading medtech companies, including key roles in multiple start-ups leading to acquisition.
“Dennis’s strong track record of success in sales and commercialization, ranging from start-ups to large multinationals, will be invaluable as we significantly ramp production capabilities for our MIMIX™ hydrophilic vascular access devices,” said James Biggins, Founder and CEO of Access Vascular. “We look forward to applying his extensive experience in building teams and launching new products to our mission of transforming the standard of care for vascular access.”
At more than $20,000 per incident, complications related to vascular access cost the U.S. healthcare system approximately $4.5 billion dollars annually – not to mention long-term adverse effects for patients.[iii] The innovative MIMIX™ biomaterial’s ability to lower complication rates, as seen in the aforementioned clinical studies, has the potential to make a substantial impact on those numbers [i, ii]
“The revolutionary MIMIX™ biomaterial has the potential to be a game-changer when it comes to reducing the cost and poor outcomes associated with vascular access complications,” said Byrne. “I’m looking forward to helping the AVI team improve the standard of care for patients and clinicians alike.”
About Access Vascular
Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis. Taking a foundationally different approach to thrombus reduction, the company manufactures intravenous catheters from a proprietary hydrophilic material. Engineered to mimic the body’s natural chemistry, Access Vascular catheters are designed to evade the foreign body response and the complications that come with it. Our award-winning, FDA-cleared products are HydroPICC® and HydroMID®. For more information, please visit www.accessvascularinc.com, and follow us on LinkedIn.
References
[i] Bunch J. A retrospective assessment of peripheral midline failures focusing on catheter composition. J InfusNurs. Sept/Oct 2022; 45(5):270-27
[ii] LeRoy, K. J., & Donahue, D. T. (2023). Presented at AVA 2023 via e-poster. Reduction of thrombus accumulation was evaluated using in vitro and models. Pre-clinical in vitro valuations do not necessarily predict clinical performance with respect to thrombus formation.
[iii] Moureau NL (2022). International Journal of Nursing Health Care Research 5: 1347. DOI: https://doi.org/10.29011/2688-9501.101347
